Vitaeris

Company

Also known as: Vitaeris

Company Profile

Vitaeris was a clinical-stage biotechnology company focused on clazakizumab development for antibody-mediated rejection and was based in Vancouver. It was founded in 2016 and acquired by CSL Behring in 2020.

Website: https://www.vitaerisbio.com
Headquarters: Vancouver, British Columbia, Canada
Founded: 2016

Related News

Eli Lilly Acquires Rights to CSL's IL-6 Inhibitor in $100M Deal

Mar 26, 2026

Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.

Eli Lilly Licenses Clazakizumab from CSL in $100 Million Deal

Feb 18, 2026

CSL Limited has licensed global development and commercialization rights for clazakizumab to Eli Lilly outside of ESKD-related cardiovascular risk. CSL receives $100 million upfront and retains rights to the ESKD indication.